Wordt geladen...
Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma
The prognosis for patients with recurrent glioblastomas (GBMs) is dismal, with a median survival of 3–6 months. We performed a phase II trial of low-dose continuous (metronomic) treatment using temozolomide (TMZ) for recurrent GBMs. TMZ-refractory patients with GBM who experienced disease recurrence...
Bewaard in:
| Hoofdauteurs: | , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Oxford University Press
2010
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2940595/ https://ncbi.nlm.nih.gov/pubmed/20167817 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nop030 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|